Diagnosis and management of thrombosis in pregnancy

Pregnancy‐related thrombosis is a major cause of maternal mortality. Pregnancy and the puerperium are associated with a fourfold to fivefold increased risk of thrombosis when compared with the nonpregnant state. The greatest time of risk is in the postpartum period. Diagnosis of venous thromboemboli...

Full description

Saved in:
Bibliographic Details
Published in:Birth defects research. Part C. Embryo today 2015-09, Vol.105 (3), p.185-189
Main Author: Konkle, Barbara A.
Format: Article
Language:English
Subjects:
Anticoagulants
Anticoagulants - therapeutic use
anticoagulation
Birth defects
Congenital defects
Diagnosis
Diagnostic systems
Embolism
Female
Health risk assessment
Heparin
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Postpartum
Pregnancy
Pregnancy Complications, Hematologic - diagnosis
Pregnancy Complications, Hematologic - therapy
Puerperium
Pulmonary Embolism - diagnosis
Pulmonary Embolism - therapy
Radiation
Risk Factors
Thromboembolism
Thrombosis
Thrombosis - diagnosis
Thrombosis - therapy
venous thromboembolism
Venous Thrombosis - diagnosis
Venous Thrombosis - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pregnancy‐related thrombosis is a major cause of maternal mortality. Pregnancy and the puerperium are associated with a fourfold to fivefold increased risk of thrombosis when compared with the nonpregnant state. The greatest time of risk is in the postpartum period. Diagnosis of venous thromboembolism (VTE) during pregnancy can be challenging as many of the symptoms can be associated with normal pregnancy. Almost all deep venous thrombosis occurs in the left leg or iliac veins. Diagnostic procedures for pulmonary embolism carry some exposure to radiation, although risks are low when compared with risks associated with an undiagnosed maternal PE. The anticoagulant of choice during pregnancy is low‐molecular‐weight heparin. Certain medical conditions require alternative approaches as management around the time of delivery. In women with VTE during pregnancy, anticoagulation should continue for at least 3 months and until at least 6 weeks postpartum. Birth Defects Research (Part C) 105:185–189, 2015. © 2015 Wiley Periodicals, Inc.
ISSN:1542-975X
1542-9768
DOI:10.1002/bdrc.21104